Marshall Wace
GYRE icon

Marshall Wace’s Gyre Therapeutics GYRE Stock Holding History

Marshall Wace’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,720
Closed -$128K – 2682
2024
Q2 		$128K Sell
10,720
-14,824
-58% -$203K ﹤0.01% 2378
2024
Q1 		$447K Buy
+25,544
New +$460K ﹤0.01% 1976
2022
Q1 		– Sell
-9,014
Closed -$61K – 3599
2021
Q4 		$61K Buy
+9,014
New +$154K ﹤0.01% 3514
2020
Q3 		– Sell
-1,874
Closed -$83K – 1717
2020
Q2 		$83K Buy
+1,874
New +$88K ﹤0.01% 1467
2020
Q1 		– Sell
-16,743
Closed -$855K – 1811
2019
Q4 		$855K Buy
+16,743
New +$702K 0.01% 1021
2019
Q2 		– Sell
-15,729
Closed -$957K – 1539
2019
Q1 		$957K Sell
15,729
-46,671
-75% -$3M 0.01% 943
2018
Q4 		$3.69M Sell
62,400
-10,745
-15% -$792K 0.04% 545
2018
Q3 		$5.91M Sell
73,145
-235
-0.3% -$18.6K 0.05% 423
2018
Q2 		$6.42M Buy
+73,380
New +$12.9M 0.1% 249

Other funds holding GYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AACP
Advantage Alpha Capital Partners San Francisco, California $332M AUM 12.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Marshall Wace's GYRE Position: Q3 2024 in Review

Marshall Wace sold out of Gyre Therapeutics (GYRE) in Q3 2024, closing a stake of 10,720 shares — an estimated $128K sold.

Marshall Wace first reported a position in GYRE in Q2 2018 and held it in 9 quarters. The position peaked at $6.42M in Q2 2018. 37 funds tracked by Wall St. Rank hold GYRE as of Q3 2024.

  • Marshall Wace reported no remaining Gyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 10,720 Gyre Therapeutics shares in Q3 2024, an estimated $128K.
  • Marshall Wace first reported a position in Gyre Therapeutics in Q2 2018 and held it in 9 quarters.
  • Marshall Wace's Gyre Therapeutics position peaked at $6.42M in Q2 2018.
  • 37 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.